Search results
Showing 1 to 2 of 2 results for ta600
This guidance has been updated and replaced by NICE technology appraisal guidance 770.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.